This prospective, observational study will evaluate the efficacy, safety and tolerability of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or are intolerant to one or more conventional disease-modifying anti-rheumatic drugs. Data will be collected from patients initiated on RoActemra/Actemra treatment according to the local label at baseline, Weeks 4, 12 and 24, and at 3 and 6 months after the last dose of study drug.

Inclusion Criteria:

• Adult patients, >/= 21 years of age
• Moderate to severe active rheumatoid arthritis (DAS28 >/= 3.2)
• Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)
• Initiated on RoActemra/Actemra treatment in accordance with the prescribing information

Exclusion Criteria:

• Pregnant or lactating women
• Contra-indication to RoActemra/Actemra treatment according to the local labelling
• Previous treatment with tocilizumab
• Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra
• Women of childbearing potential not using effective methods of contraception as defined by protocol

Patients with moderate to severe rheumatoid arthritis and an inadequate response or intolerant to previous therapy with conventional DMARDs